

DAFTAR PUSTAKA

1. Harsono AB. Kanker Ovarium : “The Silent Killer.” *Indones J Obstet Gynecol Sci.* 2020;3(1):1-6. doi:10.24198/obgynia.v3n1.192
2. Marina Tandarto; Erwin Ginting; M. Khairul Nuryanto. Hubungan Usia Menarche Dengan Kejadian Kanker Ovarium. *Husada Mahakam J Kesehat.* 2020;V(2):71-77.
3. Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. *Cancer Biol Med.* 2017;14(1):9-32. doi:10.20892/j.issn.2095-3941.2016.0084
4. Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018. *CA Cancer J Clin.* 2018;68(4):284-296. doi:10.3322/caac.21456
5. International Agency for Research on Cancer (IARC). Indonesia - Global Cancer Observatory. *Globocan.* 2020;858:1-2.
6. Malik YA, Friadi A. Perbandingan Akurasi Skor ROMA dan IOTA dalam Prediksi Keganasan Tumor Ovarium. *J Obgin Emas.* 2020;4(1):70-76. doi:10.25077/aoj.4.1.70-76.2020
7. Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world : epidemiology and risk factors. Published online 2019:287-299.
8. Trihandini I, Nurrika D. Analisis Ketahanan Hidup Penderita Kanker Ovarium Epithelial di RS Dharmais Jakarta. *J Kesehat Masy Nas Vol 5, No 3, Desember 2010.* 2010;5:139-144.
9. Jones PM, Drapkin R. Modeling high-grade serous carcinoma: How converging insights into pathogenesis and genetics are driving better experimental platforms. *Front Oncol.* 2013;3 AUG(August):1-10. doi:10.3389/fonc.2013.00217
10. Budiana ING, Angelina M, Pemayun TGA. Ovarian cancer: Pathogenesis and current recommendations for prophylactic surgery. *J Turkish-German Gynecol Assoc.* 2019;20(1):47-54. doi:10.4274/jtgga.galenos.2018.2018.0119
11. Rambe IR, Asri A, Adrial A. Profil Tumor Ganas Ovarium di Laboratorium Patologi Anatomi Fakultas Kedokteran Universitas Andalas Periode Januari 2011 Sampai Desember 2012. *J Kesehat Andalas.* 2014;3(1):54-57. doi:10.25077/jka.v3i1.26
12. Salazar C, Campbell IG, Gorringer KL. When Is “type I” Ovarian Cancer Not “type I”? Indications of an Out-Dated Dichotomy. *Front Oncol.* 2018;8(December):1-9. doi:10.3389/fonc.2018.00654
13. Asri Adisasmita, Dini Maryani BD. Hubungan antara Menyusui dengan

Risiko Kanker Ovarium. 2016;10(3):93-102.

14. Jeong SY, Park BK, Lee YY, Kim T-J. Validation of IOTA-ADNEX Model in Discriminating Characteristics of Adnexal Masses: A Comparison with Subjective Assessment. *J Clin Med.* 2020;9(6):2010. doi:10.3390/jcm9062010
15. Meys EMJ, Jeelof LS, Achten NMJ, et al. Estimating risk of malignancy in adnexal masses: external validation of the ADNEX model and comparison with other frequently used ultrasound methods. *Ultrasound Obstet Gynecol.* 2017;49(6):784-792. doi:10.1002/uog.17225
16. Araujo KG, Jales RM, Pereira PN, et al. Performance of the IOTA ADNEX model in preoperative discrimination of adnexal masses in a gynecological oncology center. *Ultrasound Obstet Gynecol.* 2017;49(6):778-783. doi:10.1002/uog.15963
17. Sayasneh A, Ferrara L, De Cock B, et al. Evaluating the risk of ovarian cancer before surgery using the ADNEX model: A multicentre external validation study. *Br J Cancer.* 2016;115(5):542-548. doi:10.1038/bjc.2016.227
18. Hu J, Shi Y, Li M, Yi C. Clinical Performance of ADNEX (The Assessment of Different NEoplasias in the adneXa) Model in Early Diagnosis and Staging of Benign and Malignant Ovarian Tumors. *Yangtze Med.* 2017;01(03):148-156. doi:10.4236/ym.2017.13015
19. Chen H, Qian L, Jiang M, Du Q, Yuan F, Feng W. Performance of IOTA ADNEX model in evaluating adnexal masses in a gynecological oncology center in China. *Ultrasound Obstet Gynecol.* 2019;54(6):815-822. doi:10.1002/uog.20363
20. Triana E, Dr. D, Serudji J, Dr. A. The accuracy of modified risk malignancy index (RMI) in predicting malignancy of epithelial type ovarian cancer. *Indones DJ Obstet Gynecol.* 2019;7(3):228-232. doi:10.32771/inajog.v7i3.900
21. Van Calster B, Van Hoorde K, Froyman W, et al. Practical guidance for applying the ADNEX model from the IOTA group to discriminate between different subtypes of adnexal tumors. *Facts, views Vis ObGyn.* 2015;7(1):32-41.
<http://www.ncbi.nlm.nih.gov/pubmed/25897370>
<http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC4402441>
22. Snell RS. *Anatomi Klinis Berdasarkan Sistem*. Penerbit Buku Kedokteran EGC; 2012.
23. Leslie P, Gartner JLH. *Concise Histology*. In: Elsevier; 2011.
24. Mescher AL. *Histologi Dasar Junqueira Teks & Atlas*. 12th ed. Penerbit Buku Kedokteran EGC; 2012.

25. Dwi ariningtyas N. CA 125 dan Pemakaian Klinis Dalam Penatalaksanaan Kanker Ovarium. *Qanun Med - Med J Fac Med Muhammadiyah Surabaya*. 2018;2(2):73-82. doi:10.30651/jqm.v2i2.1657
26. Fadillah A, Friadi A. Case Report Metastasis of Residive Mucinous Ovarian Carcinoma to Umbilicus , Peritoneum , And Ascites Fluid With No Malignancy Marker Found in The Previous Post-Operative Histopathological Examination. Published online 2019:130-136.
27. Katabuchi H. *Comprehensive Gynecology and Obstetrics Frontiers in Ovarian Cancer Science*. <http://www.springer.com/series/13621>
28. Katabuchi H. *Frontiers in Ovarian Cancer Science*; 2017. <http://link.springer.com/10.1007/978-981-10-4160-0>
29. Sataloff RT, Johns MM, Kost KM. *No Berek & Novak's Gynecology*. Fifteenth. (Deborah L.Berek M, ed.). Lippincott williams & Wilkins; 2012.
30. Kurman RJ, Shih IM. The origin and pathogenesis of epithelial ovarian cancer: A proposed unifying theory. *Am J Surg Pathol*. 2010;34(3):433-443. doi:10.1097/PAS.0b013e3181cf3d79
31. Sattar HA. Sistem Genitalia Wanita dan Payudara. In: Mangunkusumo RR, ed. *Buku Ajar Patologi Robbins*. 9th ed. Elsevier; 2015:671-704.
32. Chen VW, Ruiz B, Killeen JL, et al. Pathology and classification of ovarian tumors. *Cancer*. 2003;97(10 SUPPL.):2631-2642. doi:10.1002/cncr.11345
33. Partridge BL. Background Camouflage: an Additional Parameter in Hermit Crab Shell Selection and Subsequent Behavior. *Bull Mar Sci*. 1980;30(304):28-62. doi:10.1097/PAS.0b013e3181cf3d79.The
34. Rosen DG, Yang G, Liu G, et al. Ovarian cancer: Pathology, biology, and disease models. *Front Biosci*. 2009;14(6):2089-2102. doi:10.2741/3364
35. Gilks TAL and CB. Epithelial Neoplasms of the Ovary. In: Nucci MR, ed. *Gynecologic Pathology*. 2nd ed. Elsevier; 2021:577-639.
36. Turunen R. Experiences of Sym-Flo Headbox and Automatic Profile Control. *Papermak Conf Proc Tech Assoc Pulp Pap Ind*. Published online 1986:233-236.
37. Arania R, Windarti I. Karakteristik Pasien Kanker Ovarium di Rumah Sakit Dr . H . Abdul Moeloek Ovarian Cancer Characteristic in H . Abdul Moeloek Hospital Bandar Lampung 2009-2013 Period. *J Kedokt Unila*. 2015;5:43-47.
38. Veny K Yantie AK. Tumor Ovarium: Prediksi Kegansan Prabedah. *Ikhtisar Pustaka*. 2012;4:31-36.
39. Rahmawati H, Darmawaty ER RDP. Kanker Ovarium Disgerminoma. *Indones J Clin Pathol Med Lab*. 2012;19(1):51-55.

40. Braat DDM. Diagnosis and management of ovarian disorders. *Eur J Obstet Gynecol Reprod Biol.* 1997;72(2):217. doi:10.1016/s0301-2115(96)02679-6
41. Jones R. Ovarian Cancer Tests and Treatment. *Bone.* 2014;23(1):1-7. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3624763/pdf/nihms412728.pdf>
42. VolSJ. Journal homepage: <http://jos.unsoed.ac.id/index.php/mandala/index>. 2018;11(1):18-30. doi:10.20884/1.mandala.2018.11.1.535
43. American Cancer Society. Ovarian Cancer Early Detection, Diagnosis, and Staging. *Am Cancer Soc.* Published online 2017:1-25. <https://www.cancer.org/cancer/prostate-cancer/detection-diagnosis-staging.html>
44. Prat J, Belhadj H, Berek J, et al. Figo's staging classification for cancer of the ovary, fallopian tube, and peritoneum: Abridged republication. *J Gynecol Oncol.* 2015;26(2):87-89. doi:10.3802/jgo.2015.26.2.87
45. Larsson SC, Eoli M, Finocchiaro G, et al. NCCN. (2016). NCCN Guidelines Version 1.2016 Epithelial Ovarian Cancer/Fallopian Tube Cancer/ Primary Peritoneal Cancer & Less Common Histopathologies. *Encycl Cancer.* Published online 2011:2671-2674. http://www.springerlink.com/index/10.1007/978-3-642-16483-5_4295
46. Van Calster B, Van Hoorde K, Valentin L, et al. Evaluating the risk of ovarian cancer before surgery using the ADNEX model to differentiate between benign, borderline, early and advanced stage invasive, and secondary metastatic tumours: Prospective multicentre diagnostic study. *BMJ.* 2014;349(October):1-14. doi:10.1136/bmj.g5920
47. Dhitayoni Ayu Ida BGNI. Profil Pasien Kanker Ovarium di Rumah Sakit Umum Pusat Sanglah Denpasar - Bali Periode Juli 2013 - Juni 2014. 2017;6(3):125-131.
48. Lim AWW, Mesher D, Gentry-Maharaj A, et al. Time to diagnosis of Type i or II invasive epithelial ovarian cancers: A multicentre observational study using patient questionnaire and primary care records. *BJOG An Int J Obstet Gynaecol.* 2016;123(6):1012-1020. doi:10.1111/1471-0528.13447
49. Skirnisdottir I, Seidal T, Åkerud H. Differences in clinical and biological features between type i and Type II Tumors in FIGO Stages I-II epithelial ovarian carcinoma. *Int J Gynecol Cancer.* 2015;25(7):1239-1247. doi:10.1097/IGC.0000000000000484
50. Kroeger PT, Drapkin R. Pathogenesis and heterogeneity of ovarian cancer. *Curr Opin Obstet Gynecol.* 2017;29(1):26-34. doi:10.1097/GCO.0000000000000340
51. Chesang JJ. Pathogenesis Of Ovarian Cancer : Current Perspectives.

2017;94(7):561-574.

52. Survival I, Europe CC-, Funders PMC. The Histology of Ovarian Cancer : Worldwide Distribution and Implications for Europe PMC Funders Group The Histology of Ovarian Cancer: Worldwide Distribution and Implications for International Survival Comparisons. 2017;144(February):405-413. doi:10.1016/j.ygyno.2016.10.019.The
53. Choi JH, Wong AST, Huang HF, Leung PCK. Gonadotropins and ovarian cancer. *Endocr Rev.* 2007;28(4):440-461. doi:10.1210/er.2006-0036

